摘要
目的:探讨病灶组织抑癌基因p16的表达与胃腺癌患者化疗后2年和5年生存率之间的关系.方法:选择2004-03/2007-02来我院接受治疗的胃腺癌晚期患者47例作为观察组,均接受XELOX(奥沙利铂+希罗达)方案化疗.选择25例健康志愿者作为对照组.采用免疫组织化学检测观察组和对照组患者胃黏膜组织上皮组织内p16表达情况,并比较观察组病灶组织p16低表达和正常表达组2年和5年生存率.结果:观察组p16阳性率为17.4%±3.6%,显著低于对照组(P<0.05).p16正常表达组有19例(40.43%),低表达组有28例(59.57%).p16低表达组16例患者经化疗后2年生存6例(31.58%),5年生存4例(21.05%),均显著低于p16正常表达组(P<0.05).结论:p16过低表达胃腺癌患者化疗预后较差,且p16基因表达可以作为预测胃腺癌XELOX方案化疗预后.
AIM： To investigate the relationship between p16 expression and the 2- and 5-year survival rates in patients with gastric adenocarcinoma treated with XELOX chemotherapy.
METHODS： Forty-seven patients with advanced gastric adenocarcinoma, who received XELOX （oxaliplatin ＋ capecitabine） treatment from March 2006 to February 2007, were included in the study. Twenty-five healthy volunteers were used as controls. Immunohistochemistry was performed to detect p16 expression in gastric mucosal epithelial tissues. The 2- and 5-year survival rates were compared between patients low p16 expression and those with normal expression.
RESULTS： The positive rate of p16 expression was significantly lower in the observation than in the control group （17.4% ± 3.6% vs 43.7% ± 17.4%, P 〈 0.05）. There were 19 cases （40.43%） who had normal p16 expression, and 28 cases （59.57%） had low expression. The 2- and 5-year survival rates were significantly lower in patients with low p16 expression than in those with normal expression （31.58% vs 64.29%, 21.05% vs 50%, both P 〈 0.05）.
CONCLUSION： Patients with low p16 expression have poor prognosis after XELOX chemotherapy, and p16 expression can be used to predict prognosis in patients with gastric adenocarcinoma treated with XELOX chemotherapy.
出处
《世界华人消化杂志》
CAS
北大核心
2013年第26期2724-2727,共4页
World Chinese Journal of Digestology
关键词
胃腺癌
p16
奥沙利铂
卡培他滨
Gastric adenocarcinoma, P16
Oxalipla-tin, Capecitabine
